Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142115 |
| CAS No | NA |
| Mol.F. | C20H20Cl2N2O5 |
| Mol.Wt. | 439.29 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142116 |
| CAS No | NA |
| Mol.F. | C16H12Cl2N2O6 |
| Mol.Wt. | 399.18 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142117 |
| CAS No | NA |
| Mol.F. | C9H8N2O4 |
| Mol.Wt. | 208.17 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142118 |
| CAS No | NA |
| Mol.F. | C9H9ClN2O2 |
| Mol.Wt. | 212.63 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142119 |
| CAS No | NA |
| Mol.F. | C5H8N2O4S |
| Mol.Wt. | 192.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142120 |
| CAS No | NA |
| Mol.F. | C10H14N4O8S2 |
| Mol.Wt. | 382.36 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142121 |
| CAS No | NA |
| Mol.F. | C7H10N2O5S |
| Mol.Wt. | 234.23.g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142122 |
| CAS No | NA |
| Mol.F. | C9H18N2O5S |
| Mol.Wt. | 266.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142123 |
| CAS No | NA |
| Mol.F. | C5H8N2O6S |
| Mol.Wt. | 224.19 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142124 |
| CAS No | NA |
| Mol.F. | C8H12N2O5S |
| Mol.Wt. | 248.25 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142125 |
| CAS No | NA |
| Mol.F. | C5H8N2O4S |
| Mol.Wt. | 192.19 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142126 |
| CAS No | NA |
| Mol.F. | C8H13N3O6S2 |
| Mol.Wt. | 311.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142127 |
| CAS No | NA |
| Mol.F. | C5H4N6O2 |
| Mol.Wt. | 180.13 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142128 |
| CAS No | NA |
| Mol.F. | C9H12N6O5 |
| Mol.Wt. | 284.23 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142129 |
| CAS No | NA |
| Mol.F. | C18H23N5O6S |
| Mol.Wt. | 437.47 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142130 |
| CAS No | NA |
| Mol.F. | C17H21N5O6S |
| Mol.Wt. | 423.44 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |